Daniel specialises in advising and representing national and international clients in the life sciences sector. His focus is, among others, on all areas of pharmaceutical law, medical device law, pharmaceutical-advertising law, unfair competition law, and trademark law.

 

For more than 10 years, he has been coordinating and supervising disputes concerning competition law and trademark law for his clients and has, besides his specific focus on litigation, also longstanding experience in advising clients on regulatory and compliance matters, particularly, in the aforementioned areas of law. In context with managing litigation and advising his clients, Daniel is characterised by a strong client focus and his ability to find appropriate and efficient solutions to legal problems.

显示完整简历 隐藏完整简历

最新新闻和观点

酒店与休闲

Telehealth advertising admissible if accepted professional standards are observed

2022年5月18日
Briefing

作者 Dr. Daniel Tietjen

点击此处了解更多
酒店与休闲

TAMG – the new Veterinary Medicinal Products Act

2022年5月18日
Briefing

作者 Dr. Daniel Tietjen

点击此处了解更多
酒店与休闲

Mandatory e-prescription rollout postponed

2022年5月18日
Briefing

作者 Dr. Daniel Tietjen

点击此处了解更多
Interface - FoodTech

The current regulatory framework for the marketing of products containing CBD

CBD in food and cosmetics: These requirements must be achieved for biscuits, muesli, soap and co. to be approved for the European internal market.

2022年4月25日
Briefing

作者 Dr. Daniel Tietjen

3 / 4 观点

点击此处了解更多

与我会面: